Marker Therapeutics (MRKR) Total Non-Current Liabilities (2011 - 2023)
Marker Therapeutics (MRKR) posted quarterly Total Non-Current Liabilities of $2.9 million for Q2 2023, down 73.0% year-over-year from $10.8 million in Q2 2022, and down 57.19% quarter-over-quarter from $6.8 million in Q1 2023.
Marker Therapeutics (MRKR) Total Non-Current Liabilities (2011 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Total Non-Current Liabilities for 10 consecutive years, with $2.9 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Total Non-Current Liabilities fell 73.0% year-over-year to $2.9 million; the TTM figure through Jun 2023 stood at $2.9 million (down 73.0% YoY), while the FY2022 annual figure was $7.0 million, down 37.42% from the prior year.
- Total Non-Current Liabilities fell to $2.9 million in Q2 2023 per MRKR's latest filing, from $6.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $11.9 million in Q3 2020 and bottomed at $226111.0 in Q1 2020.
- Historically, Total Non-Current Liabilities has averaged $7.0 million across 5 years, with a median of $8.1 million in 2020.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities surged 5083.22% — and 2023, when it slumped 73.0%.
- Marker Therapeutics' Total Non-Current Liabilities stood at $280247.0 in 2019, then jumped by 4134.99% to $11.9 million in 2020, then fell by 5.23% to $11.2 million in 2021, then sank by 37.42% to $7.0 million in 2022, then sank by 58.51% to $2.9 million in 2023.
- Business Quant data shows MRKR's Total Non-Current Liabilities at $2.9 million in Q2 2023, $6.8 million in Q1 2023, and $7.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2.92 Mn |
| Mar 31, 2023 | 6.82 Mn |
| Dec 31, 2022 | 7.04 Mn |
| Sep 30, 2022 | 7.23 Mn |
| Jun 30, 2022 | 10.82 Mn |
| Mar 31, 2022 | 11.04 Mn |
| Dec 31, 2021 | 11.25 Mn |
| Sep 30, 2021 | 11.43 Mn |
| Jun 30, 2021 | 11.57 Mn |
| Mar 31, 2021 | 11.72 Mn |
| Dec 31, 2020 | 11.87 Mn |
| Sep 30, 2020 | 11.95 Mn |
| Jun 30, 2020 | 9.03 Mn |
| Mar 31, 2020 | 226,111.00 |
| Dec 31, 2019 | 280,247.00 |
| Sep 30, 2019 | 333,480.00 |
| Jun 30, 2019 | 385,169.00 |
| Mar 31, 2019 | 435,192.00 |
| Dec 31, 2015 | -19.85 Mn |
| Sep 30, 2015 | -25.97 Mn |